Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
RTX-1363S in Sarcoma: NCT06298916 Clinical Landscape Report 2026
16 October 2026
NCT06298916 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Carboplatin in Recurrent Cervical Cancer: NCT06297811 Clinical Landscape Report 2026
16 October 2026
NCT06297811 clinical landscape for Recurrent Cervical Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Enfortumab Vedotin-ejfv in Renal Medullary Carcinoma: NCT06302569 Clinical Landscape Report 2026
16 October 2026
NCT06302569 clinical landscape for Renal Medullary Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Renal Cell Carcinoma: NCT06307431 Clinical Landscape Report 2026
16 October 2026
NCT06307431 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab biosimilar(R-Pharm) in Melanoma, Cutaneous Malignant: NCT06307093 Clinical Landscape Report 2026
16 October 2026
NCT06307093 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IPN-01194 in Pancreatic Ductal Adenocarcinoma: NCT06305247 Clinical Landscape Report 2026
16 October 2026
NCT06305247 clinical landscape for Pancreatic Ductal Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
RAD-204 in Metastatic Solid Tumor: NCT06305962 Clinical Landscape Report 2026
16 October 2026
NCT06305962 clinical landscape for Metastatic Solid Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LUCAR-20SP in Large B-cell lymphoma: NCT06313957 Clinical Landscape Report 2026
16 October 2026
NCT06313957 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sirolimus Albumin-Bound in Leiomyosarcoma: NCT06308419 Clinical Landscape Report 2026
16 October 2026
NCT06308419 clinical landscape for Leiomyosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RD-06-04 in Systemic Lupus Erythematosus: NCT06310811 Clinical Landscape Report 2026
16 October 2026
NCT06310811 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Camrelizumab in Triple Negative Breast Cancer: NCT06313463 Clinical Landscape Report 2026
16 October 2026
NCT06313463 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Inaticabtagene Autoleucel in Lupus Nephritis: NCT06316791 Clinical Landscape Report 2026
16 October 2026
NCT06316791 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.